1. New Trends in Treatment for Major Depressive Disorder

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Major Depressive Disorder

5. Lifetime Prevalence of a Major Depressive Episode

6. Biological Basis of MDD

7. Recognizing MDD: Guidelines and Diagnostic Criteria

8. Social and Environmental Risks Factors for Developing MDD

9. Importance of a Correct Diagnosis

10. Need to Consider Comorbidities When Making Treatment Decisions

11. Identifying Treatment-Resistant Depression

12. Questions to Consider While Participating in this Program

13. Recommendations and Tools For Assessing the Effect of Treatment for Major Depressive Disorder

14. Guidelines for the Treatment of MDD

15. Guidelines and Goals of Treatment

16. Early Improvement in the First 2 Weeks of Treatment Is Indicator of Later Response

17. Increase in Positive Mood at 2 Weeks is a Predictor of Positive Treatment Response

18. Clinicians May Appreciate Information From Scales but Seldom Use Them

19. Commonly Used Rating Scales for MDD

20. Patients' Expectations From Antidepressant Treatment

21. A Simple Approach to Assessment

22. Defining Treatment-Resistant Depression

23. Today's Approaches to Treatment for Major Depressive Disorder

24. The Mechanism of Action of Antidepressant Drugs: The Role of Monoamines

25. Systematic Review and Network Meta-Analysis of 21 Antidepressant Drugs for MDD: Efficacy Comparison

26. Primary Outcome Results for the Network Meta-Analysis: Acceptability

27. Remission Rates With Antidepressants Evaluated in STAR
Remission Rates With Antidepressants Evaluated in STAR*D: According to Lines of Treatment

28. Treatment Strategies When First-Line Treatment Fails

29. Nonpharmacologic Approaches to MDD and TRD

30. Closing Remarks

31. Future Treatment Outlook: What's New or Around the Corner in Major Depressive Disorder?

32. Ketamine: Mechanism of Action

33. Opiate Involvement in Attenuating Antidepressant Effects of Ketamine

34. Intranasal Esketamine: Phase 3 Programme

35. Efficacy of Intranasal Esketamine in TRD: Randomized, Double-Blind Study

36. Continued Esketamine Plus Antidepressant: Delay in Relapse in Patients With TRD

37. Long-Term Efficacy and Safety of Esketamine Nasal Spray in TRD

38. Brexanolone Injection in Postpartum Depression: Phase 3 Trials

39. Other Compounds for MDD or TRD in Phase 2 or 3 Trials